Company intelligence / Profile preview
Qingdao Haichuan Center for Innovative Biomedical Research
Qingdao, Shandong, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Qingdao Haichuan has developed several herbal-based therapeutics. Tongfengkang Granules is their lead program, currently in Phase 2 trials targeting acute gouty arthritis. Baixiangdan capsule has demonstrated efficacy in animal models of premenstrual dysphoric disorder by modulating gene expression linked to neuroactive ligand-receptor interactions. Clinical results suggest significant symptom alleviation but detailed human trial data is limited or not publicly available. Pipeline breadth is at least two main programs with additional traditional medicine formulations possible.
- Therapeutic areas
- Rare DiseasesPsychiatryDermatologyEndocrinologyRheumatologyWomen's Health
- Modalities
- Herbal medicine
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Beyond the preview
Go deeper on Qingdao Haichuan Center for Innovative Biomedical Research.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Qingdao Haichuan Center for Innovative Biomedical Research.